PriceTargets.com logo

Nemaura Medical - NMRD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 3,746.15%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.07 As of 04/24/2024 01:00 AM ET
▲ +0.01 (18.18%)

This chart shows the closing price for NMRD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nemaura Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMRD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMRD

Analyst Price Target is $2.50
▲ +3,746.15% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nemaura Medical in the last 3 months. The average price target is $2.50, with a high forecast of $2.50 and a low forecast of $2.50. The average price target represents a 3,746.15% upside from the last price of $0.07.

This chart shows the closing price for NMRD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Nemaura Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$7.00 ➝ $2.50Low
3/30/2023EF Hutton Acquisition Co. IReiterated RatingBuy$6.00Low
2/28/2023EF Hutton Acquisition Co. IReiterated RatingBuy$6.00Low
2/27/2023HC WainwrightLower Target$8.00 ➝ $7.00Low
8/19/2022HC WainwrightLower TargetBuy$12.00 ➝ $8.00Low
3/29/2022HC WainwrightInitiated CoverageBuy$12.00High
7/12/2021Ascendiant Capital MarketsBoost TargetBuy$15.00 ➝ $17.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Nemaura Medical logo
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Read More

Today's Range

Now: $0.07
Low: $0.06
High: $0.08

50 Day Range

MA: $0.08
Low: $0.07
High: $0.10

52 Week Range

Now: $0.07
Low: $0.06
High: $1.25

Volume

44,065 shs

Average Volume

81,759 shs

Market Capitalization

$2.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Nemaura Medical?

The following Wall Street analysts have issued stock ratings on Nemaura Medical in the last twelve months: HC Wainwright.
View the latest analyst ratings for NMRD.

What is the current price target for Nemaura Medical?

1 Wall Street analysts have set twelve-month price targets for Nemaura Medical in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 3,746.2%. HC Wainwright has the highest price target set, predicting NMRD will reach $2.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.50 for Nemaura Medical in the next year.
View the latest price targets for NMRD.

What is the current consensus analyst rating for Nemaura Medical?

Nemaura Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NMRD will outperform the market and that investors should add to their positions of Nemaura Medical.
View the latest ratings for NMRD.

What other companies compete with Nemaura Medical?

Other companies that are similar to Nemaura Medical include ProSomnus, Tenon Medical, Dynatronics, Quoin Pharmaceuticals and ProSomnus. Learn More about companies similar to Nemaura Medical.

How do I contact Nemaura Medical's investor relations team?

Nemaura Medical's physical mailing address is 57 WEST 57TH STREET, MANHATTAN NY, 10019. The company's listed phone number is (646) 416-8000 and its investor relations email address is [email protected]. The official website for Nemaura Medical is nemauramedical.com. Learn More about contacing Nemaura Medical investor relations.